| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 167.31K | 167.31K | 600.14K | 487.50K | 65.41K | 0.00 |
| Gross Profit | 162.81K | 162.81K | 294.86K | 466.01K | 65.41K | 0.00 |
| EBITDA | -4.85M | -4.85M | -1.67M | -1.36M | -3.42M | -1.43M |
| Net Income | -4.65M | -4.59M | -3.29M | -1.42M | -3.17M | -2.73M |
Balance Sheet | ||||||
| Total Assets | 3.41M | 3.41M | 329.69K | 1.51M | 2.04M | 3.59M |
| Cash, Cash Equivalents and Short-Term Investments | 2.00M | 2.00M | 216.86K | 14.56K | 525.24K | 3.49M |
| Total Debt | 198.19K | 198.19K | 197.72K | 859.98K | 261.34K | 320.29K |
| Total Liabilities | 855.77K | 855.77K | 1.54M | 1.79M | 1.55M | 1.51M |
| Stockholders Equity | 2.60M | 2.60M | -1.17M | -247.46K | 1.08M | 2.31M |
Cash Flow | ||||||
| Free Cash Flow | -3.99M | -3.99M | -1.64M | -634.28K | -3.02M | -959.00K |
| Operating Cash Flow | -3.99M | -3.99M | -1.64M | -634.28K | -3.02M | -931.35K |
| Investing Cash Flow | -1.15K | -1.15K | -325.98K | -210.64K | -1.14M | -11.38K |
| Financing Cash Flow | 5.78M | 5.78M | 2.16M | 374.37K | 1.27M | 4.17M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | C$32.09M | -6.38 | ― | ― | -48.53% | -9.66% | |
44 Neutral | C$8.97M | ― | ― | ― | 12.44% | 74.38% | |
38 Underperform | C$12.70M | -1.47 | -1143.80% | ― | -64.23% | 18.42% | |
34 Underperform | C$11.83M | ― | ― | ― | ― | 21.61% | |
34 Underperform | C$64.31M | -4.89 | -202.19% | ― | ― | 40.17% |
AI/ML Innovations Inc. has announced the granting of a U.S. patent for its core ECG signal-processing architecture, which enhances its competitive edge as it moves towards commercialization and regulatory approval. This patent solidifies AIML’s intellectual property position, supporting its strategies in cardiology, remote monitoring, telehealth, and clinical research applications, and underscores the company’s commitment to expanding its IP portfolio.
AI/ML Innovations Inc.’s subsidiary, NeuralCloud Solutions, has partnered with Lonacas Consultants to lead the regulatory submission for its CardioYield™ software in Jamaica. This collaboration is a strategic move to expand NeuralCloud’s presence in the Caribbean by providing affordable, high-quality cardiac diagnostics. The initiative aims to address the growing cardiovascular disease burden in Jamaica by introducing a cost-effective, AI-enhanced ECG monitoring solution. The CardioYield™ platform, combined with a wearable chest strap, promises to improve access to cardiac care, particularly in regions with limited diagnostic resources. This regulatory process is crucial for ensuring the technology’s compliance with local standards and its successful deployment across healthcare facilities in Jamaica.
AI/ML Innovations Inc. announced that its subsidiary, NeuralCloud Solutions, is launching a pilot program with a Canadian cardiology clinic to implement its AI-powered ECG analysis platform, CardioYield™. This initiative aims to enhance the accuracy and efficiency of Holter ECG analysis through advanced AI signal processing, potentially improving clinical workflows and diagnostic precision. The pilot will start with internal validation, followed by in-clinic testing, and aims for full integration pending regulatory clearance. This collaboration represents a significant step in AIML’s mission to deliver AI-driven healthcare solutions and could set a benchmark for AI-driven reporting improvements in cardiology.
AI/ML Innovations Inc.’s subsidiary, NeuralCloud Solutions, in collaboration with Heartdent Center Ltd., has launched a pilot project in Jamaica to advance cardiac care using their AI-powered platform, CardioYield™. This initiative aims to provide affordable, accurate, and scalable Holter diagnostics, addressing the urgent need for accessible cardiac diagnostics in Jamaica, where cardiovascular disease is a leading cause of death. The pilot project will evaluate the integration and operational impact of CardioYield™ in Heartdent Center’s practice, potentially setting new standards for patient-centered care and improving patient outcomes through timely and accurate diagnosis.
AI/ML Innovations Inc.’s subsidiary, NeuralCloud Solutions, has launched a pilot program with the Toronto Heart Centre to test CardioYield™, an AI-powered Holter ECG reporting tool. The study aims to evaluate the efficiency and quality improvements in ECG analysis and reporting compared to current industry standards. This collaboration is expected to enhance clinical workflows, benefiting both clinicians and patients by potentially improving speed and diagnostic reliability.
AI/ML Innovations Inc. has announced a pilot project in collaboration with the BC Brain Wellness Program to explore the heart-brain connection using its MaxYield ECG technology. This initiative aims to analyze cardiac responses in individuals with neurological conditions during exercise, potentially uncovering insights into the relationship between heart activity and brain health. The project marks an important step in expanding AIML’s technology into neurology, with implications for future clinical research and improved care through interdisciplinary AI applications.
AI/ML Innovations Inc. announced the successful closing of an oversubscribed private placement, raising $2,128,595, exceeding its initial target of $1,550,000. The funds will be used for general working capital, and the placement involved significant insider participation, constituting a related party transaction under regulatory guidelines. Additionally, the company extended the expiry date of existing share purchase warrants from a previous financing round, reflecting its strategic financial management.
AI/ML Innovations Inc. announced a non-brokered private placement offering of up to 31,000,000 units at $0.05 per unit, aiming to raise $1,550,000. The proceeds will be used for working capital, and the offering includes common shares and warrants, subject to a hold period. The placement is contingent on necessary approvals, and finder’s fees may be paid to those assisting in the sale.
AIML Innovations Inc. has filed an amended and restated management’s discussion and analysis to address disclosure deficiencies identified by the British Columbia Securities Commission. The amendments include enhanced disclosure on new strategic initiatives, R&D activities, operational results, acquisitions, and payments to related parties. Additionally, the filing discusses an exit agreement with Tech2Heal and other minor changes. This move aims to improve transparency and provide stakeholders with a clearer understanding of the company’s recent activities and strategic direction.